1. BRAFV600E mutation test on fine‐needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients
    Huang Chen et al, 2022, Cancer Medicine CrossRef
  2. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas
    Emilie Wang et al, 2015, Anti-Cancer Drugs CrossRef
  3. The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives
    Veronica Vella et al, 2018, International Journal of Molecular Sciences CrossRef
  4. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
    Martin Schlumberger et al, 2015, New England Journal of Medicine CrossRef
  5. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage
    Augustas Beiša et al, 2017, Langenbeck's Archives of Surgery CrossRef

  6. Lenvatinib-Induced Acute Pancreatitis in a Patient with Metastatic Thyroid Cancer: A Case Report


    Hong Jun Kim et al, 2020, International Journal of General Medicine CrossRef
  7. Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis
    Chunping Liu et al, 2016, World Journal of Surgical Oncology CrossRef
  8. BRAF‐V600E immunohistochemistry in a large series of glial and glial–neuronal tumors
    Quentin Breton et al, 2017, Brain and Behavior CrossRef
  9. CD8+ tumour‐infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer
    Lucas Leite Cunha et al, 2015, Clinical Endocrinology CrossRef
  10. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta‐analysis
    Zhen Wang et al, 2016, European Journal of Clinical Investigation CrossRef
  11. First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma
    Bao D. Dao et al, 2015, Journal of Investigative Medicine High Impact Case Reports CrossRef
  12. BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma
    Brendon Mitchell et al, 2016, Advances in Anatomic Pathology CrossRef
  13. The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis
    Xin Li et al, 2020, Cancers CrossRef
  14. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer
    Claudia Martinuzzi et al, 2016, Endocrine CrossRef
  15. The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer
    Jose R. W. Martínez et al, 2019, Hormones and Cancer CrossRef